Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia

American Journal of Cardiology

Volumn 91, Issue 8, 2003, Pages 961-964

  Lucas, Charles P ^b   Boldrin, Mark N ^b   Reaven, Gerald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LOW CALORY DIET; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0345701533     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00112-7     Document Type: Article

References (14)

1. Sjostrom L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H.P., Krempf M. Randomized placebo-controlled trial of orlistat of weight loss and prevention of weight regain in obese patients. Lancet. 352:1998;167-172.
2. Davidson M.H., Hauptman J., DiGirolamo M., Foreyt J.P., Halsted C.H., Heber D., Heimburger D.C., Lucas C.P., Robbins D.C., Chung J. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA. 281:1999;235-242.
3. Rossner S., Sjostrom L., Noack R., Meinders A.E., Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 8:2000;49-61.
4. Assmann G., Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PRO-CAM experience). Am J Cardiol. 70:1992;733-737.
5. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Mänttäri M., Heininen O.P., Frick M.H. Joint effects of serum triglycerides and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study; implications for treatment. Circulation. 85:1992;37-45.
6. Sheu W.H.-H., Shieh S.-M., Fuh M.M.-T., Shen D.D.-C., Jeng C.-Y., Chen Y.-D.I., Reaven G.M. Insulin resistance, glucose intolerance, and hyperinsulinemia. Hypertriglyceridemia versus hypercholesterolemia. Arterioscl Thromb. 13:1993;367-370.
7. Reaven G.M., Segal K., Hauptman J., Boldrin M., Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol. 87:2001;827-831.
8. Tietz N.W. Fundamentals of Clinical Chemistry. 3rd Ed: 1987;W.B. Saunders Company, Philadelphia, PA.
9. Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J 1963;88:137-146.
10. Warnick G.R., Albers J.J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 19:1978;65-76.
11. Summary of the Third Report of the National Cholesterol Education Program (NCEPT) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
12. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
13. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 81:1998;7B-12B.
14. Depres J.-P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:1996;952-957.